Burkitt's lymphoma (BL) can often be cured by intensive chemotherapy, but the toxicity of such therapy precludes its use in the elderly and in patients with endemic BL in developing countries, necessitating new strategies 1 . The normal germinal centre B cell is the presumed cell of origin for both BL and diffuse large B-cell lymphoma (DLBCL), yet gene expression analysis suggests that these malignancies may use different oncogenic pathways 2 . BL is subdivided into a sporadic subtype that is diagnosed in developed countries, the Epstein-Barr-virus-associated endemic subtype, and an HIV-associated subtype, but it is unclear whether these subtypes use similar or divergent oncogenic mechanisms. Here we used high-throughput RNA sequencing and RNA interference screening to discover essential regulatory pathways in BL that cooperate with MYC, the defining oncogene of this cancer. In 70% of sporadic BL cases, mutations affecting the transcription factor TCF3 (E2A) or its negative regulator ID3 fostered TCF3 dependency. TCF3 activated the pro-survival phosphatidylinositol-3-OH kinase pathway in BL, in part by augmenting tonic B-cell receptor signalling. In 38% of sporadic BL cases, oncogenic CCND3 mutations produced highly stable cyclin D3 isoforms that drive cell cycle progression. These findings suggest opportunities to improve therapy for patients with BL.
Burkitt's lymphoma (BL) can often be cured by intensive chemotherapy, but the toxicity of such therapy precludes its use in the elderly and in patients with endemic BL in developing countries, necessitating new strategies 1 . The normal germinal centre B cell is the presumed cell of origin for both BL and diffuse large B-cell lymphoma (DLBCL), yet gene expression analysis suggests that these malignancies may use different oncogenic pathways 2 . BL is subdivided into a sporadic subtype that is diagnosed in developed countries, the Epstein-Barr-virus-associated endemic subtype, and an HIV-associated subtype, but it is unclear whether these subtypes use similar or divergent oncogenic mechanisms. Here we used high-throughput RNA sequencing and RNA interference screening to discover essential regulatory pathways in BL that cooperate with MYC, the defining oncogene of this cancer. In 70% of sporadic BL cases, mutations affecting the transcription factor TCF3 (E2A) or its negative regulator ID3 fostered TCF3 dependency. TCF3 activated the pro-survival phosphatidylinositol-3-OH kinase pathway in BL, in part by augmenting tonic B-cell receptor signalling. In 38% of sporadic BL cases, oncogenic CCND3 mutations produced highly stable cyclin D3 isoforms that drive cell cycle progression. These findings suggest opportunities to improve therapy for patients with BL.
We performed RNA resequencing (RNA-seq) on 28 sporadic BL patient biopsies and 13 BL cell lines and reanalysed published RNAseq data from 52 germinal centre B-cell-like (GCB) DLBCL cases and 28 activated B-cell-like (ABC) DLBCL cases 3 . Elimination of known single-nucleotide polymorphisms left a set of putative single-nucleotide variants, of which 95% (495 out of 518) were confirmed by Sanger sequencing (Supplementary Tables 1 and 2) .
Mutations in many genes were more frequent in BL than in DLBCL, including MYC, as well as many not previously implicated in this lymphoma subtype (Fig. 1, Supplementary Fig. 1a and Supplementary Table 1 ). Conversely, recurrently mutated genes in DLBCL [3] [4] [5] [6] [7] (EZH2, SGK1, BCL2, CD79B, MYD88) were rarely, if ever, mutated in BL. Several genes were mutated in BL and DLBCL (TP53, GNA13, MKI67, CCND3), although TP53 mutations were more common in BL ( Fig. 1 and Supplementary Fig. 1b ). This mutational survey indicates that BL is pathogenetically distinct from other germinal centre-derived lymphomas.
Highly recurrent mutations in TCF3 and its negative regulator ID3 indicated that TCF3 has a central role in BL pathogenesis, as it does in normal B-cell development by regulating the transcription of immunoglobulin and other B-cell-restricted genes through E-box motifs 8, 9 . ID3 and/or TCF3 mutations were present in sporadic BL, HIV-associated BL and endemic BL, in 70%, 67% and 40% of samples, respectively, but these mutations were rare in other lymphoid cancers (Fig. 2a and Supplementary Table 3) . In sporadic BL, ID3 mutations (58%) were more common than TCF3 mutations (11%), and some tumours had mutations in both genes (13%). ID3 mutations were usually bi-allelic whereas TCF3 mutations were often mono-allelic (Supplementary Fig. 2a by RNA-seq. Shown are genes that were recurrently mutated in BL based on RNA-seq analysis ($4 out of 41 samples), as well as representative genes known to be recurrently mutated in DLBCL. Asterisks indicate differentially mutated genes (P , 0.05; Supplementary Table 9 ).
(Supplementary Table 3 ). All TCF3 mutations affected the basic helixloop-helix (B-HLH) DNA-binding and dimerization domain of one TCF3 splice isoform (E47) but not the other (E12), indicating a non-redundant role for E47 in BL pathogenesis. In cases with TCF3 mutations, E47 was more highly expressed than E12, indicating gainof-function ( Supplementary Fig. 2b ). Most TCF3 mutations target four evolutionarily conserved residues in the B-HLH region (N551K, V557E/G, D561E/V/N, M572K; Supplementary Fig. 3a) . The most common mutations affect V557 and D561, which are adjacent in the crystal structure and face away from DNA, indicating a role in intermolecular interactions (Fig. 2b) . The B-HLH domain may be distorted by mutations affecting M572 and L597, which are neighbouring residues in the crystal structure. N551 is a DNA contact residue 10 , indicating that N551K could alter TCF3 DNA binding.
A variety of nonsense and frameshift mutations inactivate ID3 in BL tumours, suggesting a tumour-suppressor mechanism ( Supplementary  Fig. 3b ). Many missense mutations target the conserved loop region of ID3, potentially changing the tertiary structure of the B-HLH domain and impairing its ability to inhibit TCF3 (ref. 11, Fig. 2c ). Numerous ID3 missense mutations affect the HLH domain away from the interface of the two helices, possibly altering TCF3 interaction. Other mutations disrupt an ID3 splice donor and force a cryptic splice donor to be used, thereby deleting residues V82-Q100 (Supplementary Figs 2c and 3b ).
An RNA interference screen revealed TCF3 to be an essential gene in BL lines ( Supplementary Fig. 2d and Supplementary Table 4), supporting the notion that the TCF3 and ID3 mutations in BL promote TCF3 action. TCF3 knockdown caused a time-dependent toxicity in all BL lines, irrespective of ID3/TCF3 mutations, but had no effect on DLBCL lines (Fig. 2d and Supplementary Figs 2e and 4a, b) . Wild-type TCF3 rescued BL lines from the toxicity of RNA-interference-mediated depletion of TCF3, as did the TCF3 mutants, indicating that they are not loss-of-function ( Supplementary Fig. 2f ). Introduction of wildtype ID3 into BL lines with ID3 mutations was lethal, but BL-derived ID3 mutants had less or no toxicity, consistent with a tumoursuppressor mechanism ( Fig. 2e and Supplementary Figs 2g and 4c) .
The common ID3 and TCF3 mutants diminished their inhibitory heterodimerization. TCF3(V557E) and TCF3(D561E) did not associate well with ID3 and failed to stabilize ID3 protein expression, unlike wild-type TCF3 ( Fig. 2f and Supplementary Figs 2h and 4d) . Likewise, the ID3 mutant proteins were expressed less well than wild-type ID3 and were less able to co-immunoprecipitate TCF3 ( Fig. 2g and Supplementary Fig. 4e ). However, TCF3(N551K) behaved like wild-type TCF3 in these dimerization assays, indicating a distinct mechanism.
We next used chromatin immunoprecipitation followed by sequencing (ChIP-seq) analysis to gauge the ability of the TCF3 mutants to interact with chromatin genome-wide. We engineered two BL lines to express biotinylated wild-type or mutant TCF3 isoforms (TCF3-Biotag; see Methods), allowing us to precipitate bound chromatin with streptavidin. For comparison, we used anti-TCF3 antibodies to precipitate chromatin in unmanipulated BL cells (Supplementary Table 5 ). Both the endogenous and TCF3-Biotag ChIP-seq peaks were enriched for E-box motifs (CAG(G/C)TG) and overlapped extensively ( Supplementary Fig. 5a ). In 25-base-pair bins bound by wild-type TCF3-Biotag, the V557E, D561E and N551K isoforms had overlapping ChIP-seq tags (.7) in 98%, 98% and 92% of instances, respectively, but the overlap was only 10% for control Biotag ChIP-seq data (P , 10
2300
). Hence, all TCF3 mutants bound a large number of genomic targets equivalently.
Given the lower overlap between TCF3(N551K) and wild-type TCF3 chromatin binding, we identified genomic regions that had ID3 levels were quantified by densitometry and normalized to TCF3 E47 levels (right). g, BL-derived mutant ID3 proteins are less stable than WT ID3 and bind TCF3 less well. Mutant or WT ID3 isoforms were expressed in the ID3-deficient Namalwa BL line. The indicated proteins were detected in total cellular extracts (input) or after anti-TCF3 IP. h, TCF3(N551K) is an alteredspecificity mutant. Shown on top are DNA base frequencies of the most enriched motifs in peaks bound more than fourfold more or less by TCF3(N551K) compared to WT TCF3. The mean number (6s.e.m.) of the indicated motifs per differentially bound peak is plotted below. i, A TCF3 gene expression signature expressed in BL and normal germinal centre B cells. Gene expression changes were profiled in ID3-mutant BL lines following TCF3 knockdown or WT ID3 overexpression. Shown are genes that were downregulated by at least 0.33 log 2 in .70% of samples. Average expression of these genes in the indicated lymphoma subtypes based on published data 2 and in B-cell subpopulations based on RNA-seq is shown. Table 6 and Supplementary Fig. 5b ). In these binding regions, TCF3(V557E) and TCF3(D561E) behaved like wild-type TCF3. The peaks bound preferentially by wild-type TCF3 contained multiple copies of the motif 59-NNCACCTG-39 whereas the peaks bound preferentially by TCF3(N551K) were enriched for the sequence 59-GGCAGCTG-39 (Fig. 2h) . Whereas both motifs match the E-box consensus, these results indicate that TCF3(N551K) is an altered-specificity mutant that has somewhat different genomic targets than wild-type TCF3.
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To gain insight into the biological processes controlled by TCF3 in BL, we profiled changes in gene expression following TCF3 knockdown and following wild-type ID3 expression in ID3-mutant BL lines. We identified 139 'TCF3-upregulated' genes that were decreased in expression by both manipulations and 166 'TCF3-downregulated' genes that were increased in expression (false discovery rate (FDR) 5 0.017; Fig. 2i and Supplementary Figs 2i and 6a) . TCF3 ChIP-seq peaks were enriched among TCF3-upregulated genes (58%; P 5 1.81 3 10
229
) and among TCF3-downregulated genes (32%; P 5 1.03 3 10 24 ) ( Supplementary Fig. 6a ). We will refer to such genes as 'TCF3 direct targets'.
Most TCF3-upregulated genes were more highly expressed in BL than in DLBCL, whereas TCF3-downregulated genes were generally expressed at lower levels in BL (P # 0.001; Fig. 2i and Supplementary  Fig. 6a, b ). BL tumours with ID3 and/or TCF3 mutations had higher expression of the TCF3-upregulated signature than tumours with wild-type ID3 and TCF3, and the opposite was true for the TCF3-downregulated signature (P 5 0.0001; Supplementary Fig. 6c) . Hence, the transcriptional influence of TCF3 on the BL phenotype seems to be accentuated by ID3/TCF3 mutations. TCF3-upregulated genes were more highly expressed in germinal centre B cells than in resting or activated blood B cells, and the reverse was true for TCF3-downregulated genes ( Fig. 2i and Supplementary Fig. 6a ), indicating that BL 'inherits' the TCF3 gene expression program from its normal cellular counterpart.
Biological insights from this analysis include the fact that the negative regulators of TCF3-ID1, ID2 and ID3-were direct targets of TCF3 transactivation, thereby creating a negative feedback loop ( Fig. 2i and Supplementary Fig. 5a ). By RNA-seq, ID3 was 38-fold and 12-fold more highly expressed in BL than ID1 and ID2, respectively, accounting for the preferential mutation of ID3 in BL. TCF3 also positively regulated genes that have crucial roles in germinal centre B-cell biology (POU2AF1, CXCR4, LTB, CCND3). TCF3 upregulated CCND3 and E2F2 while downregulating RB1, thereby promoting cell cycle progression.
Two components of the B-cell receptor (BCR), the immunoglobulin heavy and light chains, were both upregulated by TCF3 in BL, as in normal B cells 8, 12 ( Fig. 2i and Supplementary Figs 2i, j and 5a) . In this regard, it was notable that knockdown of the BCR subunit CD79A was toxic for several BL lines in our RNA interference screen ( Supplementary Fig. 7a ). Two-thirds of BL lines were clearly BCRdependent, on the basis of a time-dependent decrease in their viability following knockdown of either CD79A or the BCR-associated kinase SYK (Fig. 3a) . Unlike ABC DLBCL lines, which have a 'chronic active' form of BCR signalling 4 , BL lines do not require the NF-kB pathway for survival because they were not killed by an IkB kinase b inhibitor and had little or no dependence on CARD11 (ref. 13) , an adaptor that engages NF-kB ( Supplementary Fig. 7a-c) . Rather, CD79A or SYK depletion in BL lines decreased AKT phosphorylation, a marker of phosphatidylinositol-3-OH (PI(3)) kinase signalling ( Fig. 3b and Supplementary Fig. 7d ), indicating that the BCR-dependency in BL is akin to 'tonic' BCR signalling 14 , a phenomenon that engages prosurvival PI(3) kinase signalling more than NF-kB 15 . TCF3 knockdown decreased phospho-AKT levels in all BCRdependent lines tested, as did ID3 overexpression ( Fig. 3b and Supplementary Fig. 7d, e) , perhaps due to decreased cell-surface BCR expression following TCF3 depletion (Fig. 3c) . In addition, a direct TCF3 target, PTPN6, encodes the phosphatase SHP-1, an inhibitor of BCR signalling (Supplementary Figs 2j and 5a) . TCF3 depletion increased SHP-1 mRNA and protein levels, indicating (1) or empty vector (-), whereupon the indicated proteins were analysed by immunoblotting. f, BL lines have constitutively PI(3) kinase activity. The indicated proteins were analysed by immunoblotting, before and after treatment with the PI(3) kinase inhibitor LY294002. g, PI(3) kinase inhibition is toxic to BL lines. Viable BL cells were quantified by MTS assay following treatment for 4 days with the indicated concentrations of the pan-class I PI(3) kinase inhibitor BKM120. h, A signature of rapamycin-responsive genes is highly expressed in BL. Changes of gene expression were profiled over time in 2 BL lines following rapamycin (100 pM) treatment. Genes consistently downregulated in both lines were chosen (see Methods), and their expression in lymphoma biopsies 2 is shown based on the colour scale. PMBL, primary mediastinal B-cell lymphoma. i, The rapamycin-upregulated and -downregulated signatures distinguish BL and GCB DLBCL. Genes are ranked according to their expression in BL versus GCB DLBCL (T-statistic) and rapamycin signature genes are indicated with a green hash mark. KolmogorovSmirnov P values are shown.
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TCF3 repression (Fig. 3d and Supplementary Figs 2i and 6a) . Ectopic provision of SHP-1 decreased phospho-AKT in BCR-dependent BL lines, indicating that TCF3 repression of SHP-1 may contribute to tonic BCR signalling and PI(3) kinase activation in BL (Fig. 3e) .
A screen of a larger number of BL lines revealed that all had PI(3) kinase-dependent AKT phosphorylation and engagement of the mTOR pathway, as judged by phosphorylation of p70 S6 kinase (Fig. 3f) . Treatment of BL lines with BKM120, a PI(3) kinase inhibitor in clinical trials, or rapamycin, an inhibitor of the mTORC1 complex, was toxic to most BL lines (Fig. 3g and Supplementary Fig. 7f ). Of note, both BCR-dependent and -independent lines had constitutive PI(3) kinase signalling. Other mechanisms to activate PI(3) kinase in BL include PTEN mutations, which were infrequent (7%), and tenfold overexpression (compared to DLBCL) of the MYC-dependent gene MIR17HG, which encodes a microRNA that inhibits PTEN expression 16 ( Supplementary Fig. 7g ). To judge whether the PI(3) kinase pathway may be active in primary BL tumours, we identified genes that were significantly up-or downregulated following rapamycin treatment of BL lines (FDR 5 0.0022; Supplementary Table 7) . Among BL and GCB DLBCL biopsies, rapamycin-downregulated genes were generally more highly expressed in BL (P 5 0.026), whereas rapamycin-upregulated genes had the opposite enrichment pattern (P 5 0.007) (Fig. 3i) , indicating that PI(3) kinase-dependent mTORC1 activity is a consistent feature of BL tumours.
Another aspect of BL pathogenesis was revealed by recurrent mutations in the TCF3 direct target CCND3, encoding cyclin D3, a required regulator of the G1-S cell cycle transition in germinal centre B cells 17, 18 . CCND3 mutations were frequent in sporadic BL (38%) and HIVassociated BL (67%) but not endemic BL (1.8%), indicating a distinct genetic pathogenesis for this latter BL subtype (Fig. 4b) . At a lower frequency, CCND3 mutations were also present in ABC and GCB DLBCL 3, 6, 7 . Multiple nonsense and frameshift mutations removed up to 41 amino acids from the cyclin D3 C terminus (Fig. 4a and Supplementary Table 8 ). Recurrent missense mutations affected threonine 283 (T283), known to be involved in D-type cyclin phosphorylation and stability 19 , as well as nearby proline (P284) and isoleucine (I290) residues. These cyclin D3 residues were conserved in evolution, and similar residues are present in cyclin D1 and D2 (Fig. 4a) . Most mutations were heterozygous and their somatic origin was confirmed in five cases (Supplementary Table 8) .
To explore the function of the cyclin D3 mutants, we constructed fusion proteins linking green fluorescent protein (GFP) to either wildtype or mutant cyclin D3. All mutant isoforms accumulated to more than tenfold higher levels than the wild-type isoform (Fig. 4c) , and pulse-chase analysis showed that the mutant cyclin D3 isoforms have longer half lives ( Supplementary Fig. 8a ). To test the oncogenic potential of the cyclin D3 mutants, we transduced GFP-tagged wild-type or T283A cyclin D3 into lymphoma lines in which endogenous cyclin D3 was knocked down. Cells transduced with T283A cyclin D3 had a marked proliferative advantage over untransduced cells, but wild-type cyclin D3 had little effect (Fig. 4d) . Separately, our RNA interference screen revealed that BL and GCB DLBCL lines depend on cyclin D3 and CDK6, a kinase that partners with D-type cyclins, irrespective of LETTER RESEARCH
